OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer
Andre Verhoek, Parneet Cheema, Barbara Melosky, et al.
PharmacoEconomics - Open (2023) Vol. 7, Iss. 3, pp. 455-467
Open Access | Times Cited: 5
Andre Verhoek, Parneet Cheema, Barbara Melosky, et al.
PharmacoEconomics - Open (2023) Vol. 7, Iss. 3, pp. 455-467
Open Access | Times Cited: 5
Showing 5 citing articles:
Cost-Effectiveness of Adjuvant Alectinib Versus Chemotherapy for Patients with Resectable, ALK-positive Non-small Cell Lung Cancer in Canada
Nick Jovanoski, Sarah Vaselenak, Alexandra M. Hogan, et al.
PharmacoEconomics (2025)
Open Access
Nick Jovanoski, Sarah Vaselenak, Alexandra M. Hogan, et al.
PharmacoEconomics (2025)
Open Access
Cost-effectiveness of ivosidenib versus chemotherapy for previously treated IDH1-mutant advanced intrahepatic cholangiocarcinoma in Taiwan
Kuei-An Chen, Weiming Huang, Eric Yi-Ting Chen, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Kuei-An Chen, Weiming Huang, Eric Yi-Ting Chen, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Osimertinib in the treatment of resected EGFR-mutated non-small cell lung cancer: a cost-effectiveness analysis in the United States
Gengwei Huo, Ying Song, Wenjie Liu, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Gengwei Huo, Ying Song, Wenjie Liu, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Cost-effectiveness of adjuvant icotinib versus chemotherapy for patients with stage II–IIIA EGFR-mutated non-small cell lung cancer in China
Lifeng Mu, Fulin Liu, Yulan Fang, et al.
BMJ Open (2024) Vol. 14, Iss. 8, pp. e081270-e081270
Open Access
Lifeng Mu, Fulin Liu, Yulan Fang, et al.
BMJ Open (2024) Vol. 14, Iss. 8, pp. e081270-e081270
Open Access
Exploring EGFR Mutations in Resected Stage I-III NSCLC in Low- and Middle-Income Countries: Bridging the Gap in Global Cancer Care
Enrique Caballé‐Perez, Luis Cabrera‐Miranda, Óscar Arrieta
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 10, pp. 1367-1369
Closed Access
Enrique Caballé‐Perez, Luis Cabrera‐Miranda, Óscar Arrieta
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 10, pp. 1367-1369
Closed Access
Treatment for Advanced Non–Small Lung Cancer (NSCLC) with Mutated EGFR in Low- and Middle-Income Countries (LMICs)
Andrés F. Cardona, Vaneza Ávila, Óscar Arrieta
Journal of Immunotherapy and Precision Oncology (2023) Vol. 6, Iss. 4, pp. 185-186
Open Access
Andrés F. Cardona, Vaneza Ávila, Óscar Arrieta
Journal of Immunotherapy and Precision Oncology (2023) Vol. 6, Iss. 4, pp. 185-186
Open Access
